Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Japan Tobacco, Inc.
  6. News
  7. Summary
    2914   JP3726800000

JAPAN TOBACCO, INC.

(2914)
  Report
Delayed Japan Exchange  -  01:00:00 2023-01-27 am EST
2675.50 JPY   -0.04%
01/25JUUL Labs Reportedly in Deal Talks with Three Tobacco Giants
CI
01/25Consumer Cos Up After Mixed Earnings -- Consumer Roundup
DJ
01/25Juul in deal talks with three tobacco giants - WSJ
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Japan Tobacco : Top-line Results of Phase 3 Clinical Study of JTE-052 Ointment, JAK Inhibitor, in Infant Patients with Atopic Dermatitis in Japan

12/14/2021 | 01:08am EST

Japan Tobacco Inc. (JT)(TSE:2914) and Torii Pharmaceutical Co., Ltd. (Torii) (TSE:4551) announced today the top-line results of Phase 3 study in infant patients with atopic dermatitis in Japan for JTE-052 (generic name: delgocitinib) ointment, a Janus kinase (JAK) inhibitor. Delgocitinib ointment has been developed in Japan for patients with atopic dermatitis by JT and Torii under the terms of an agreement for co-development and marketing in Japan, signed in October 2016.

This study is an open-label, uncontrolled study to evaluate the efficacy and safety of delgocitinib ointment 0.25% and 0.5% over 52 weeks in infant patients with atopic dermatitis (aged 6 to <24 months), conducted in Japan. The top-line results as of the 28th week of treatment show the delgocitinib ointment's effect in improving skin eczema. The safety of the ointment within the treatment period was also confirmed. Based on these results and other clinical studies, JT and Torii will aim to submit a manufacturing and marketing application for delgocitinib ointment in Japan.

Torii also distributes delgocitinib ointment under the brand name CORECTIM®in Japan, where CORECTIM®Ointment 0.5% is approved for the treatment of adults and pediatric atopic dermatitis, and CORECTIM®Ointment 0.25% is approved for the treatment of pediatric atopic dermatitis.

ABOUT Atopic Dermatitis
Atopic dermatitis is a chronic and pruritic inflammatory skin disease. It is thought to develop through exposure to various irritation or allergens for patients with a physiological abnormality of the skin (dry skin and abnormal skin barrier function).

###

Japan Tobacco Inc. is a leading international tobacco company with operations in more than 130 countries. With approximately 58,000 employees, it manufactures and sells some of the world's best-known brands including Winston, Camel, MEVIUS and LD. The JT Group is committed to investing in Reduced-Risk Products (RRP) and currently markets its heated tobacco products under the Ploom brand and various e-cigarette products under its Logic brand. The Group is also present in the pharmaceutical and processed food businesses.

Disclaimer

Japan Tobacco Inc. published this content on 14 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 December 2021 06:07:06 UTC.


ę Publicnow 2021
All news about JAPAN TOBACCO, INC.
01/25JUUL Labs Reportedly in Deal Talks with Three Tobacco Giants
CI
01/25Consumer Cos Up After Mixed Earnings -- Consumer Roundup
DJ
01/25Juul in deal talks with three tobacco giants - WSJ
RE
01/25Juul Explores Potential Sale, Investment Or Distribution Deal With Philip Morris, Japan..
RE
01/20Japan Tobacco urged to sell drug unit by activist shareholder LIM
RE
2022Japan's Nikkei closes off 3-mth low, pressured by Wall Street weakness
RE
2022JAPAN TOBACCO, INC. : Ex-dividend day for final dividend
FA
2022Japan's Nikkei touches 3-month low on Wall Street weakness
RE
2022Foreigners net buyers of Japanese stocks for second straight week
RE
2022Nikkei 225 Up 0.3% on Earnings Season, Fed Outlook
MT
More news
Analyst Recommendations on JAPAN TOBACCO, INC.
More recommendations
Financials
Sales 2022 2 585 B 19 900 M 19 900 M
Net income 2022 424 B 3 266 M 3 266 M
Net Debt 2022 203 B 1 564 M 1 564 M
P/E ratio 2022 11,1x
Yield 2022 6,47%
Capitalization 4 749 B 36 551 M 36 551 M
EV / Sales 2022 1,92x
EV / Sales 2023 1,86x
Nbr of Employees 55 381
Free-Float 54,4%
Chart JAPAN TOBACCO, INC.
Duration : Period :
Japan Tobacco, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JAPAN TOBACCO, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Last Close Price 2 675,50 JPY
Average target price 2 618,43 JPY
Spread / Average Target -2,13%
EPS Revisions
Managers and Directors
Masamichi Terabatake Director
Nobuya Kato Chief Financial Officer & Senior Vice President
Mutsuo Iwai Chairman
Hiroyuki Miki Executive Officer, Head-Research & Development
Kazuhito Yamashita Manager-Company Environment Promotions
Sector and Competitors
1st jan.Capi. (M$)
JAPAN TOBACCO, INC.0.54%36 551
ALTRIA GROUP, INC.-3.43%79 106
ITC LIMITED4.36%52 686
KT&G CORPORATION2.73%8 876
PT HANJAYA MANDALA SAMPOERNA TBK16.07%7 570
RLX TECHNOLOGY INC.12.61%4 009